Florida’s HIV Funding Cuts: A Looming Public Health Crisis
A recent emergency rule in Florida has drastically reduced eligibility for the state’s AIDS Drug Assistance Program (ADAP), sparking concerns about a potential surge in HIV infections and compromised patient care. The cuts, driven by a reported $120 million budget deficit, impact an estimated 16,000 residents and raise critical questions about access to essential HIV medication.
The Impact of Reduced ADAP Eligibility
Previously, Florida’s ADAP program covered individuals at or below 400% of the federal poverty level. The new rule restricts eligibility to those at or below 130% of the poverty level, significantly limiting access for lower-income and uninsured individuals. This change could leave thousands without the means to afford life-saving treatment.
Modern HIV medications allow individuals to reduce their viral load to undetectable levels, enabling them to live essentially normal lifespans. Disrupting access to these medications has serious consequences, potentially leading to increased viral transmission and worsening health outcomes.
Biktarvy No Longer Covered
The Florida ADAP formulary no longer includes Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), a common once-daily pill that accounts for 52% of new or changed prescriptions for HIV medication. This removal further restricts treatment options for those relying on the program.
Expert Concerns and Projected Infection Rates
“This news is devastating,” stated Aadia Rana, MD, an infectious diseases professor at the University of Alabama at Birmingham. “In a state that has the third highest rates of both new cases as well as those living with HIV in this country, any potential interruptions in HIV therapy… has the potential to increase the rate of uncontrolled virus and worsen outcomes for people living with HIV in Florida.”
Preliminary analysis by Melissa Schnure, PhD, a senior epidemiologist at the Johns Hopkins University School of Medicine, suggests the cuts could lead to 4,312 more HIV infections in Florida between 2026 and 2030 – a 28% increase compared to projections if ADAP remained unchanged. This analysis echoes findings from a recent simulation study showing a 73% surge in U.S. HIV infections if the federal Ryan White HIV/AIDS Program were eliminated.
A National Trend of Funding Cuts
Florida is not alone in facing HIV funding reductions. Data from the National Association of State and Territorial AIDS Directors (NASTAD) indicates that 23 states, along with Washington, D.C., have implemented or are considering cuts to ADAP, though none as drastic as Florida’s.
The Broader Implications for Public Health
HIV advocates estimate that up to 16,000 of the 30,000 currently enrolled in the Florida ADAP could lose eligibility. Anna K. Person, MD, chair of the HIV Medicine Association, warned that these cuts will impact communities throughout the state, threaten lives, and potentially lead to spikes in new HIV diagnoses and increased healthcare costs.
“HIV treatment disruptions of this magnitude will result in a public health disaster. Florida must follow due process and function with health care professionals, people with HIV and the state legislature to address any funding challenges,” Person stated.
FAQ: Florida’s ADAP Cuts
- What is ADAP? The AIDS Drug Assistance Program helps low-income and uninsured individuals access HIV medications.
- How many people in Florida are affected? Approximately 16,000 residents are estimated to lose eligibility.
- What is the projected increase in HIV infections? Analysis suggests a potential 28% increase in new infections between 2026 and 2030.
- Is this happening in other states? Yes, 23 states and Washington, D.C., are considering or have implemented ADAP cuts.
For more information:
- Aadia Rana, MD: [email protected]
- Melissa Schnure, PhD: [email protected]
Sources:
Disclosures: Rana and Schnure report no relevant financial disclosures.
What are your thoughts on the Florida ADAP cuts? Share your perspective in the comments below.
Worth a look